£1m grant breakthrough for prostate cancer

Study co-author Professor Paul Workman, Chief Executive of the ICR, said: "This study has uncovered a remarkably large number of new genes that drive the development of prostate cancer, and given us vital information about how to exploit the biology of the disease to find potential new treatments".

The study - which is the largest and most comprehensive ever conducted into the genes that drive prostate cancer - found that around a quarter of these mutations involve the targets of existing drugs that are either licensed or in clinical trials. This suggests that these could offer promise for further study as new approaches to treatment. Additionally, 60 new potential targets for prostate cancer treatment were identified for future investigation, as well as identifying many new genes associated with the development of the disease.

Source: Masonic Charitable Foundation